Diffusion-weighted MR images (DWI_MRI) acquired 12 weeks after the start of neoadjuvant chemotherapy for breast cancer may provide the best indication of how patients will respond to treatment, according to a study published in Radiology.
The researchers analyzed 242 participants who were randomized to receive 12 weekly doses of paclitaxel with four cycles of anthracycline. The MRI protocol included, DWI imaging T2-weighted and contrast enhanced sequences.
The authors concluded that after 12 weeks of therapy, change in breast tumor apparent diffusion coefficient at MRI predicts complete pathologic response to neoadjuvant chemotherapy
No comments:
Post a Comment